%PDF-1.6
%
1 0 obj
<>
endobj
2 0 obj
<>stream
Rebecca Kahn, Annette Rid, Peter G. Smith, Nir Eyal, Marc Lipsitch
Choices in vaccine trial design in epidemics of emerging infections
www.plosmedicine.org
www.plosmedicine.org
endstream
endobj
3 0 obj
<>/XObject<>>>/CropBox[0 0 612 792]/MediaBox[0 0 612 792]/Parent 11 0 R/Annots 12 0 R/Contents 13 0 R/TrimBox[0 0 612 792]>>
endobj
12 0 obj
[14 0 R 15 0 R 16 0 R 17 0 R 18 0 R 19 0 R 20 0 R 21 0 R 22 0 R 23 0 R 24 0 R]
endobj
14 0 obj
<>/Border[0 0 0]/Dest(Rpmed.1002632.ref001)>>
endobj
15 0 obj
<>/Border[0 0 0]/Dest(Rpmed.1002632.ref002)>>
endobj
16 0 obj
<>/Border[0 0 0]/Dest(Rpmed.1002632.ref003)>>
endobj
17 0 obj
<>/Border[0 0 0]/Dest(Rpmed.1002632.ref004)>>
endobj
18 0 obj
<>/Border[0 0 0]/Dest(Rpmed.1002632.ref005)>>
endobj
19 0 obj
<>/Border[0 0 0]/Dest(Rpmed.1002632.ref006)>>
endobj
20 0 obj
<>/Border[0 0 0]/Dest(Rpmed.1002632.ref007)>>
endobj
21 0 obj
<>/Border[0 0 0]/Dest(Rpmed.1002632.ref008)>>
endobj
22 0 obj
<>/Border[0 0 0]/Dest(Rpmed.1002632.ref009)>>
endobj
23 0 obj
<>/Border[0 0 0]/Dest(Rpmed.1002632.t001)>>
endobj
24 0 obj
<>/Border[0 0 0]/A 25 0 R>>
endobj
25 0 obj
<>
endobj
13 0 obj
[26 0 R 27 0 R 28 0 R 29 0 R 30 0 R 31 0 R 32 0 R 33 0 R 34 0 R 35 0 R 36 0 R 37 0 R 38 0 R 39 0 R]
endobj
26 0 obj
<>stream
q
0.955 g
0 w
199.9998 713.9999 m
575.9997 713.9999 l
575.9997 654.9999 l
199.9998 654.9999 l
f*
0.83 0.64 0.02 0 k
237.2031 513.5811 m
241.9654 513.5811 l
h
f*
244.1764 513.5811 m
248.9386 513.5811 l
h
f*
335.2252 461.5937 m
339.9874 461.5937 l
h
f*
239.1874 435.5717 m
243.9496 435.5717 l
h
f*
246.2173 435.5717 m
250.9795 435.5717 l
h
f*
203.4142 252.2835 m
208.1764 252.2835 l
h
f*
210.3874 252.2835 m
215.1496 252.2835 l
h
f*
344.126 161.2346 m
348.8882 161.2346 l
h
f*
351.1559 161.2346 m
355.9181 161.2346 l
h
f*
200.0126 94.9039 m
229.2094 94.9039 l
h
f*
0 g
1 j
1 J
10 0 0 10 217.8141 696.9826 cm
BT
/F5 1 Tf
1 TL
0.005 Tc
0 0 Td
(stepped)Tj
3.3505 0 Td
(rollout)Tj
2.9877 0 Td
(may)Tj
1.9559 0 Td
(be)Tj
1.1678 0 Td
(necessary,)Tj
4.337 0 Td
(in)Tj
1.0545 0 Td
(which)Tj
2.6929 0 Td
(recruitment)Tj
5.091 0 Td
(to)Tj
1.0431 0 Td
(the)Tj
1.4967 0 Td
(trial)Tj
1.8822 0 Td
(is)Tj
0.8674 0 Td
(staggered)Tj
4.0705 0 Td
(over)Tj
2.0126 0 Td
(a)Tj
-34.0098 -1.2982 Td
(period.)Tj
ET
Q
q
1 j
1 J
0 w
11.9999 0 0 11.9999 200.0125 596.6929 cm
BT
/F2 1 Tf
1 TL
-0.0033 Tc
0 0 Td
(Introduction)Tj
ET
Q
q
1 j
1 J
0 w
10 0 0 10 200.0125 579.685 cm
BT
/F5 1 Tf
1 TL
-0.004 Tc
0 0 Td
(In)Tj
1.1055 0 Td
(outbreaks)Tj
4.1498 0 Td
(of)Tj
1.0148 0 Td
(emerging)Tj
4.0025 0 Td
(infectious)Tj
4.1329 0 Td
(diseases)Tj
3.3789 0 Td
(for)Tj
1.3833 0 Td
(which)Tj
2.6532 0 Td
(no)Tj
1.2756 0 Td
(proven)Tj
3.0387 0 Td
(efficacious)Tj
4.4334 0 Td
(vaccines)Tj
3.5546 0 Td
(exist)Tj
2.0353 0 Td
(but)Tj
-36.1585 -1.3039 Td
(investigational)Tj
6.0377 0 Td
(vaccines)Tj
3.5546 0 Td
(have)Tj
2.0636 0 Td
(been)Tj
2.1203 0 Td
(developed,)Tj
4.4958 0 Td
(it)Tj
0.788 0 Td
(is)Tj
0.8447 0 Td
(important)Tj
4.286 0 Td
(both)Tj
2.0579 0 Td
(to)Tj
1.0261 0 Td
(rapidly)Tj
3.0388 0 Td
(test)Tj
1.5987 0 Td
(the)Tj
1.474 0 Td
(investiga-)Tj
-33.3862 -1.2982 Td
(tional)Tj
2.5171 0 Td
(vaccines)Tj
3.5603 0 Td
(and,)Tj
1.9559 0 Td
(if)Tj
0.771 0 Td
(effective,)Tj
3.736 0 Td
(to)Tj
1.0262 0 Td
(deploy)Tj
2.897 0 Td
(them.)Tj
2.5171 0 Td
(Following)Tj
4.2179 0 Td
(the)Tj
1.4684 0 Td
(20142016)Tj
4.5411 0 Td
(Ebola)Tj
2.4831 0 Td
(epidemic,)Tj
4.1159 0 Td
(the)Tj
-35.807 -1.2983 Td
(World)Tj
2.8346 0 Td
(Health)Tj
2.9196 0 Td
(Organization)Tj
5.5219 0 Td
(\(WHO\),)Tj
3.6056 0 Td
(the)Tj
1.4684 0 Td
(Coalition)Tj
3.9571 0 Td
(for)Tj
1.389 0 Td
(Epidemic)Tj
4.0308 0 Td
(Preparedness)Tj
5.5446 0 Td
(Innovations,)Tj
-31.2716 -1.3039 Td
(and)Tj
1.7291 0 Td
(other)Tj
2.347 0 Td
(bodies)Tj
2.812 0 Td
(committed)Tj
4.6091 0 Td
(to)Tj
1.0205 0 Td
(developing)Tj
4.6034 0 Td
(investigational)Tj
6.0378 0 Td
(vaccines)Tj
3.5603 0 Td
(for)Tj
1.3833 0 Td
(emerging)Tj
4.0024 0 Td
(infectious)Tj
-32.1049 -1.2983 Td
(diseases)Tj
3.3788 0 Td
([)Tj
0.83 0.64 0.02 0 k
(1)Tj
0 g
(,)Tj
0.83 0.64 0.02 0 k
(2)Tj
0 g
(].)Tj
2.3017 0 Td
(They)Tj
2.2337 0 Td
(aim)Tj
1.7405 0 Td
(to)Tj
1.0261 0 Td
(evaluate)Tj
3.4639 0 Td
(them)Tj
2.2904 0 Td
(for)Tj
1.3833 0 Td
(immunogenicity)Tj
6.8598 0 Td
(and)Tj
1.7291 0 Td
(safety,)Tj
2.7043 0 Td
(so)Tj
1.0885 0 Td
(that)Tj
1.7801 0 Td
(promising)Tj
-31.9802 -1.2982 Td
(candidates)Tj
4.4617 0 Td
(will)Tj
1.6667 0 Td
(be)Tj
1.1509 0 Td
(available)Tj
3.668 0 Td
(for)Tj
1.3833 0 Td
(efficacy)Tj
3.2201 0 Td
(testing)Tj
2.8857 0 Td
(and)Tj
1.7291 0 Td
(possible)Tj
3.4072 0 Td
(deployment)Tj
4.989 0 Td
(when)Tj
2.4037 0 Td
(an)Tj
1.2019 0 Td
(epidemic)Tj
-32.1673 -1.2983 Td
(occurs.)Tj
1.1962 -1.3039 Td
(In)Tj
1.1111 0 Td
(the)Tj
1.4684 0 Td
(Ebola)Tj
2.4831 0 Td
(epidemic,)Tj
4.1159 0 Td
(various)Tj
3.1408 0 Td
(strategies)Tj
3.9231 0 Td
(were)Tj
2.126 0 Td
(used)Tj
2.0579 0 Td
(for)Tj
1.389 0 Td
(the)Tj
1.4683 0 Td
(design)Tj
2.8119 0 Td
(of)Tj
1.0148 0 Td
(efficacy)Tj
3.2202 0 Td
(\(i.e.,)Tj
1.9275 0 Td
(Phase)Tj
2.5285 0 Td
(3\))Tj
-35.9827 -1.2983 Td
(trials)Tj
2.194 0 Td
(for)Tj
1.3889 0 Td
(investigational)Tj
6.0378 0 Td
(vaccines)Tj
3.5603 0 Td
([)Tj
0.83 0.64 0.02 0 k
(3)Tj
0 g
(].)Tj
1.5987 0 Td
(Some)Tj
2.4434 0 Td
(investigators)Tj
5.2781 0 Td
(argued)Tj
2.9707 0 Td
(for)Tj
1.389 0 Td
(individually)Tj
4.9889 0 Td
(randomized)Tj
-31.8498 -1.2983 Td
(controlled)Tj
4.3199 0 Td
(trials)Tj
2.194 0 Td
(\(iRCTs\),)Tj
3.651 0 Td
(while)Tj
2.3698 0 Td
(others)Tj
2.7099 0 Td
(argued)Tj
2.9707 0 Td
(for)Tj
1.3833 0 Td
(forms)Tj
2.5681 0 Td
(of)Tj
1.0148 0 Td
(cluster-randomized)Tj
8.0617 0 Td
(controlled)Tj
4.32 0 Td
(trials)Tj
-35.5632 -1.3039 Td
(\(cRCTs\))Tj
3.5773 0 Td
([)Tj
0.83 0.64 0.02 0 k
(4)Tj
0 g
(,)Tj
0.83 0.64 0.02 0 k
(5)Tj
0 g
(].)Tj
2.3017 0 Td
(Later)Tj
2.2903 0 Td
(in)Tj
1.0319 0 Td
(the)Tj
1.4683 0 Td
(epidemic,)Tj
4.1159 0 Td
(rapidly)Tj
3.0387 0 Td
(declining)Tj
3.9401 0 Td
(disease)Tj
3.0161 0 Td
(incidence)Tj
4.0705 0 Td
(required)Tj
3.6397 0 Td
(changes)Tj
3.4072 0 Td
(to)Tj
-35.8977 -1.2982 Td
(some)Tj
2.33 0 Td
(trial)Tj
1.8369 0 Td
(designs.)Tj
3.4015 0 Td
(Ideally,)Tj
3.1181 0 Td
(principles)Tj
4.1612 0 Td
(and)Tj
1.7292 0 Td
(protocols)Tj
3.9571 0 Td
(based)Tj
2.4718 0 Td
(on)Tj
1.2756 0 Td
(scientific,)Tj
4.0138 0 Td
(ethical,)Tj
3.0671 0 Td
(and)Tj
1.7291 0 Td
(feasibility)Tj
-33.0914 -1.2983 Td
(considerations)Tj
6.0661 0 Td
(should)Tj
2.914 0 Td
(be)Tj
1.1508 0 Td
(drawn)Tj
2.7893 0 Td
(up)Tj
1.2642 0 Td
(in)Tj
1.0318 0 Td
(advance)Tj
3.4696 0 Td
(of)Tj
1.0148 0 Td
(an)Tj
1.2019 0 Td
(epidemic,)Tj
4.1159 0 Td
(facilitating)Tj
4.456 0 Td
(expediency)Tj
4.6942 0 Td
(and)Tj
-34.1686 -1.3039 Td
(trust)Tj
2.0749 0 Td
(for)Tj
1.389 0 Td
(rapid,)Tj
2.5625 0 Td
(early)Tj
2.1486 0 Td
(implementation)Tj
6.6387 0 Td
(once)Tj
2.1203 0 Td
(an)Tj
1.2019 0 Td
(epidemic)Tj
3.8891 0 Td
(occurs.)Tj
-20.8288 -1.2983 Td
(Here,)Tj
2.4321 0 Td
(we)Tj
1.3266 0 Td
(summarize)Tj
4.6601 0 Td
(key)Tj
1.5931 0 Td
(scientific,)Tj
4.0138 0 Td
(ethical,)Tj
3.0671 0 Td
(and)Tj
1.7291 0 Td
(feasibility)Tj
4.0365 0 Td
(considerations)Tj
6.0604 0 Td
(relevant)Tj
3.4243 0 Td
(to)Tj
1.0261 0 Td
(the)Tj
-34.5654 -1.2982 Td
(design)Tj
2.8119 0 Td
(of)Tj
1.0148 0 Td
(Phase)Tj
2.5228 0 Td
(3)Tj
0.6973 0 Td
(vaccine)Tj
3.1975 0 Td
(trials)Tj
2.194 0 Td
(in)Tj
1.0375 0 Td
(epidemic)Tj
3.8891 0 Td
(situations.)Tj
4.3143 0 Td
(Trial)Tj
2.1486 0 Td
(design)Tj
2.8177 0 Td
(choices)Tj
3.1521 0 Td
(are)Tj
1.4456 0 Td
(discussed,)Tj
-31.2432 -1.304 Td
(highlighting)Tj
5.0909 0 Td
(the)Tj
1.4684 0 Td
(benefits)Tj
3.3392 0 Td
(and)Tj
1.7291 0 Td
(drawbacks)Tj
4.4617 0 Td
(of)Tj
1.0148 0 Td
(each)Tj
2.0296 0 Td
(in)Tj
1.0318 0 Td
(given)Tj
2.3811 0 Td
(contexts.)Tj
ET
Q
q
1 j
1 J
0 w
11.9999 0 0 11.9999 200.0125 322.3559 cm
BT
/F2 1 Tf
1 TL
-0.0033 Tc
0 0 Td
(Scope)Tj
ET
Q
q
1 j
1 J
0 w
10 0 0 10 200.0125 305.348 cm
BT
/F5 1 Tf
1 TL
-0.004 Tc
0 0 Td
(When)Tj
2.6815 0 Td
(designing)Tj
4.0989 0 Td
(and)Tj
1.7291 0 Td
(implementing)Tj
5.862 0 Td
(randomized)Tj
5.0627 0 Td
(efficacy)Tj
3.2201 0 Td
(trials)Tj
2.1997 0 Td
(for)Tj
1.3833 0 Td
(investigational)Tj
6.0434 0 Td
(vaccines)Tj
-32.2807 -1.3039 Td
(after)Tj
2.0352 0 Td
(safety)Tj
2.4775 0 Td
(and)Tj
1.7291 0 Td
(immunogenicity)Tj
6.8598 0 Td
(data)Tj
1.9162 0 Td
(have)Tj
2.0579 0 Td
(been)Tj
2.1203 0 Td
(collected)Tj
3.7418 0 Td
(\(in)Tj
1.3776 0 Td
(Phase)Tj
2.5228 0 Td
(1)Tj
0.6973 0 Td
(and)Tj
1.7291 0 Td
(2)Tj
0.6974 0 Td
(trials\),)Tj
2.7609 0 Td
(some)Tj
2.3301 0 Td
(key)Tj
-35.053 -1.2982 Td
(choices)Tj
3.1521 0 Td
(must)Tj
2.228 0 Td
(be)Tj
1.1508 0 Td
(made.)Tj
2.6476 0 Td
(In)Tj
1.1111 0 Td
(the)Tj
1.4684 0 Td
(current)Tj
3.1861 0 Td
(regulatory)Tj
4.32 0 Td
(system,)Tj
3.1634 0 Td
(randomized)Tj
5.057 0 Td
(trials)Tj
2.1997 0 Td
(are)Tj
1.4456 0 Td
(considered)Tj
4.6035 0 Td
(the)Tj
-35.7333 -1.2983 Td
(gold)Tj
1.9672 0 Td
(standard)Tj
3.719 0 Td
(and,)Tj
1.9559 0 Td
(except)Tj
2.7723 0 Td
(in)Tj
1.0374 0 Td
(rare)Tj
1.8199 0 Td
(circumstances,)Tj
6.1284 0 Td
(have)Tj
2.058 0 Td
(been)Tj
2.1203 0 Td
(required)Tj
3.6396 0 Td
(for)Tj
1.389 0 Td
(vaccine)Tj
3.1918 0 Td
(licensure)Tj
-31.7988 -1.2983 Td
([)Tj
0.83 0.64 0.02 0 k
(6)Tj
0 g
(,)Tj
0.83 0.64 0.02 0 k
(7)Tj
0 g
(].)Tj
2.3017 0 Td
(We)Tj
1.61 0 Td
(restrict)Tj
3.0331 0 Td
(our)Tj
1.6271 0 Td
(scope)Tj
2.4491 0 Td
(to)Tj
1.0261 0 Td
(randomized)Tj
5.0627 0 Td
(trials)Tj
2.194 0 Td
(of)Tj
1.0148 0 Td
(a)Tj
0.6576 0 Td
(single)Tj
2.5285 0 Td
(vaccine)Tj
3.1974 0 Td
(against)Tj
3.0274 0 Td
(an)Tj
1.2019 0 Td
(emerging)Tj
4.0025 0 Td
(infec-)Tj
-34.9339 -1.3039 Td
(tious)Tj
2.1769 0 Td
(disease)Tj
3.0218 0 Td
(for)Tj
1.3833 0 Td
(which)Tj
2.6532 0 Td
(no)Tj
1.2755 0 Td
(effective)Tj
3.5093 0 Td
(vaccine)Tj
3.1918 0 Td
(exists.)Tj
2.6249 0 Td
(We)Tj
1.61 0 Td
(assume)Tj
3.1465 0 Td
(that)Tj
1.7745 0 Td
(all)Tj
1.1508 0 Td
(participants,)Tj
5.1817 0 Td
(whether)Tj
3.4753 0 Td
(in)Tj
-36.1755 -1.2982 Td
(the)Tj
1.4683 0 Td
(intervention)Tj
5.176 0 Td
(or)Tj
1.0999 0 Td
(control)Tj
3.1237 0 Td
(group)Tj
2.6079 0 Td
(\(if)Tj
1.1111 0 Td
(any\),)Tj
2.2224 0 Td
(will)Tj
1.6668 0 Td
(have)Tj
2.0579 0 Td
(access)Tj
2.6475 0 Td
(to)Tj
1.0262 0 Td
(the)Tj
1.4683 0 Td
(best)Tj
1.8085 0 Td
(currently)Tj
3.8891 0 Td
(available)Tj
3.6623 0 Td
(other)Tj
-35.0359 -1.2983 Td
(preventative)Tj
5.1363 0 Td
(measures)Tj
3.9401 0 Td
(\(e.g.,)Tj
2.126 0 Td
(information)Tj
5.074 0 Td
(on)Tj
1.2756 0 Td
(how)Tj
1.9389 0 Td
(to)Tj
1.0261 0 Td
(prevent)Tj
3.2541 0 Td
(infection\).)Tj
-22.5749 -1.3039 Td
(We)Tj
1.61 0 Td
(discuss)Tj
3.0501 0 Td
(four)Tj
1.9162 0 Td
(key)Tj
1.5931 0 Td
(elements)Tj
3.7643 0 Td
(of)Tj
1.0148 0 Td
(trial)Tj
1.8369 0 Td
(design:)Tj
3.0387 0 Td
(randomization)Tj
6.1625 0 Td
(unit,)Tj
2.0863 0 Td
(trial)Tj
1.8368 0 Td
(population,)Tj
4.8189 0 Td
(compar-)Tj
-33.9248 -1.2983 Td
(ator)Tj
1.8311 0 Td
(intervention,)Tj
5.4028 0 Td
(and)Tj
1.7291 0 Td
(trial)Tj
1.8369 0 Td
(implementation.)Tj
6.8655 0 Td
(We)Tj
1.6043 0 Td
(weave)Tj
2.6419 0 Td
(into)Tj
1.8425 0 Td
(that)Tj
1.7745 0 Td
(discussion)Tj
4.3767 0 Td
(three)Tj
2.262 0 Td
(important)Tj
-32.1673 -1.2983 Td
(ethical)Tj
2.8402 0 Td
(considerations:)Tj
6.2873 0 Td
(the)Tj
1.474 0 Td
(social)Tj
2.4547 0 Td
(and)Tj
1.7348 0 Td
(scientific)Tj
3.7871 0 Td
(value)Tj
2.3017 0 Td
(of)Tj
1.0148 0 Td
(the)Tj
1.474 0 Td
(trial,)Tj
2.058 0 Td
(its)Tj
1.1508 0 Td
(riskbenefit)Tj
4.989 0 Td
(profile,)Tj
3.0614 0 Td
(and)Tj
-34.6278 -1.3039 Td
(the)Tj
1.4683 0 Td
(fairness)Tj
3.2768 0 Td
(of)Tj
1.0148 0 Td
(participant)Tj
4.5921 0 Td
(selection)Tj
3.719 0 Td
([)Tj
0.83 0.64 0.02 0 k
(8)Tj
0 g
(,)Tj
0.83 0.64 0.02 0 k
(9)Tj
0 g
(].)Tj
2.3018 0 Td
(These)Tj
2.5681 0 Td
(aspects)Tj
3.0388 0 Td
(are,)Tj
1.6724 0 Td
(in)Tj
1.0375 0 Td
(our)Tj
1.627 0 Td
(views,)Tj
2.6362 0 Td
(key)Tj
1.5931 0 Td
(to)Tj
1.0261 0 Td
(trial)Tj
1.8369 0 Td
(design)Tj
2.8119 0 Td
(in)Tj
-36.2208 -1.2982 Td
(these)Tj
2.2506 0 Td
(settings.)Tj
ET
Q
q
1 j
1 J
0 w
11.9999 0 0 11.9999 200.0125 112.9889 cm
BT
/F2 1 Tf
1 TL
-0.0033 Tc
0 0 Td
(Randomized)Tj
6.1276 0 Td
(vaccine)Tj
3.8504 0 Td
(trial)Tj
2.0362 0 Td
(design)Tj
3.4252 0 Td
(choices)Tj
3.9119 0 Td
(during)Tj
3.3213 0 Td
(epidemics)Tj
ET
Q
q
0.83 0.64 0.02 0 k
1 j
1 J
0 w
10 0 0 10 200.0125 95.9811 cm
BT
/F5 1 Tf
1 TL
-0.004 Tc
0 0 Td
(Table)Tj
2.4377 0 Td
(1)Tj
0 g
0.6973 0 Td
(summarizes)Tj
5.0173 0 Td
(the)Tj
1.474 0 Td
(major)Tj
2.6079 0 Td
(designs)Tj
3.1691 0 Td
(that)Tj
1.7802 0 Td
(have)Tj
2.0636 0 Td
(been)Tj
2.1203 0 Td
(used)Tj
2.0579 0 Td
(or)Tj
1.0998 0 Td
(proposed)Tj
3.9515 0 Td
(for)Tj
1.389 0 Td
(vaccine)Tj
3.1918 0 Td
(trials.)Tj
-33.0574 -1.2982 Td
(Some)Tj
2.4434 0 Td
(have)Tj
2.0636 0 Td
(not)Tj
1.5704 0 Td
(been)Tj
2.126 0 Td
(employed)Tj
4.1385 0 Td
(in)Tj
1.0318 0 Td
(epidemic)Tj
3.8891 0 Td
(settings.)Tj
ET
Q
q
1 j
1 J
0 w
576 737.1 m
36 737.1 l
36 737.6 l
576 737.6 l
f*
36 741.2598 134.7591 23.6976 re
W* n
q
134.7024 0 0 23.6409 36 741.3165 cm
q
/I0 Do
Q
Q
Q
q
0 0 612 792 re
W* n
1 j
1 J
0 w
36 48.0002 m
576 48.0002 l
576 47.5002 l
36 47.5002 l
f*
0.83 0.64 0.02 0 k
95.811 34.9228 m
254.3811 34.9228 l
h
f*
0 g
7.9999 0 0 7.9999 36 36 cm
BT
/F0 1 Tf
1 TL
-0.005 Tc
0 0 Td
(PLOS)Tj
2.8559 0 Td
(Medicine)Tj
4.1457 0 Td
(|)Tj
0.83 0.64 0.02 0 k
0.4748 0 Td
(https://doi.or)Tj
5.4142 0 Td
(g/10.1371/)Tj
4.6418 0 Td
(journal.pmed.1)Tj
6.4984 0 Td
(002632)Tj
0 g
4.2662 0 Td
(August)Tj
3.2882 0 Td
(7,)Tj
1.0418 0 Td
(2018)Tj
32.5136 0 Td
(2)Tj
0.7654 0 Td
(/)Tj
0.496 0 Td
(12)Tj
/F8 1 Tf
-0.025 Tc
-66.402 84.0904 Td
(following)Tj
3.5858 0 Td
(competing)Tj
4.1599 0 Td
(interests:)Tj
3.6142 0 Td
(ML)Tj
1.4457 0 Td
(has)Tj
1.5378 0 Td
(received)Tj
-14.3434 -1.3748 Td
(consulting)Tj
4.0748 0 Td
(fees/hon)Tj
3.189 0 Td
(oraria)Tj
2.3457 0 Td
(from)Tj
2.0126 0 Td
(Pfizer,)Tj
2.5016 0 Td
(Merck,)Tj
-14.1237 -1.3749 Td
(Affinivax,)Tj
3.6071 0 Td
(and)Tj
1.5874 0 Td
(Antigen)Tj
3.0331 0 Td
(Discovery)Tj
3.8906 0 Td
(and)Tj
1.5874 0 Td
(research)Tj
-13.7056 -1.3748 Td
(grants)Tj
2.5724 0 Td
(from)Tj
2.0126 0 Td
(Pfizer)Tj
2.2819 0 Td
(and)Tj
1.5874 0 Td
(PATH)Tj
2.3316 0 Td
(Vaccine)Tj
3.0968 0 Td
(Solutions.)Tj
/F7 1 Tf
-13.8827 -2.126 Td
(Abbreviati)Tj
3.9118 0 Td
(ons:)Tj
/F8 1 Tf
1.8425 0 Td
(cRCT,)Tj
2.452 0 Td
(cluster-random)Tj
5.7048 0 Td
(ized)Tj
-13.9111 -1.3748 Td
(controlled)Tj
3.9047 0 Td
(trial;)Tj
1.8142 0 Td
(iRCT,)Tj
2.2252 0 Td
(individuall)Tj
3.6992 0 Td
(y)Tj
0.6449 0 Td
(randomiz)Tj
3.4512 0 Td
(ed)Tj
-15.7394 -1.3748 Td
(controlled)Tj
3.9047 0 Td
(trial;)Tj
1.8142 0 Td
(PREVAIL,)Tj
3.8126 0 Td
(Partnership)Tj
4.493 0 Td
(for)Tj
1.2543 0 Td
(Research)Tj
-15.2788 -1.3748 Td
(on)Tj
1.1693 0 Td
(Ebola)Tj
2.2535 0 Td
(Virus)Tj
2.1402 0 Td
(in)Tj
0.8858 0 Td
(Liberia;)Tj
2.9268 0 Td
(STRIVE,)Tj
3.2882 0 Td
(Sierra)Tj
2.3953 0 Td
(Leone)Tj
-15.0591 -1.3748 Td
(Trial)Tj
1.8071 0 Td
(to)Tj
0.9496 0 Td
(Introduce)Tj
3.7772 0 Td
(a)Tj
0.6378 0 Td
(Vaccine)Tj
3.0968 0 Td
(Against)Tj
2.9835 0 Td
(Ebola;)Tj
2.4804 0 Td
(WHO,)Tj
-15.7324 -1.3748 Td
(World)Tj
2.4732 0 Td
(Health)Tj
2.5725 0 Td
(Organization.)Tj
/F7 1 Tf
-5.0457 -2.126 Td
(Provenanc)Tj
4.0394 0 Td
(e:)Tj
/F8 1 Tf
0.9496 0 Td
(Not)Tj
1.5378 0 Td
(commissio)Tj
4.1032 0 Td
(ned;)Tj
1.8141 0 Td
(externally)Tj
3.7489 0 Td
(peer-)Tj
ET
endstream
endobj
27 0 obj
<>stream
endstream
endobj
28 0 obj
<>stream
endstream
endobj
29 0 obj
<>stream
endstream
endobj
30 0 obj
<>stream
endstream
endobj
31 0 obj
<>stream
endstream
endobj
32 0 obj
<>stream
endstream
endobj
33 0 obj
<>stream
endstream
endobj
34 0 obj
<>stream
endstream
endobj
35 0 obj
<>stream
endstream
endobj
36 0 obj
<>stream
endstream
endobj
37 0 obj
<>stream
endstream
endobj
38 0 obj
<>stream
endstream
endobj
39 0 obj
<>stream
BT
0 67.465 Td
(reviewed)Tj
ET
Q
endstream
endobj
40 0 obj
<>/ColorSpace<>/XObject<>>>/CropBox[0 0 612 792]/MediaBox[0 0 612 792]/Parent 11 0 R/Annots 44 0 R/Contents 45 0 R/TrimBox[0 0 612 792]>>
endobj
43 0 obj
[/ICCBased 46 0 R]
endobj
46 0 obj
<>stream
xwTSϽ7PkhRH
H.*1 J "6DTpDQ2(C"QDqpIdy͛~kg}ֺ LX Xňg` l pBF|،l *? Y"1 P\8=W%Oɘ4M0J"Y2Vs,[|e92<se'9`2&ctI@o|N6 (.sSdl-c(2-y H_/XZ.$&\SM07#1ؙYr fYym";8980m-m(]v^DW~
emi ]P`/ u}q|^R,g+\Kk)/C_|Rax8t1C^7nfzDp柇u$/ED˦L L[B@ٹЖX!@~ (* {d+}G͋љς}WL$cGD2QZ4 E@@ A(q`1D `'u46ptc48.`R0)
@Rt CXCP%CBH@Rf[(t
CQhz#0 Zl`O828.p|O×X
?:0FBx$ !i@ڐH[EE1PL⢖V6QP>U(j
MFk t,:.FW8c1L&ӎ9ƌaX:
rbl1
{{{;}#tp8_\8"Ey.,X%%Gщ1-9ҀKl.oo/O$&'=JvMޞ